Georgia Salanti
Overview
Explore the profile of Georgia Salanti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
19666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Buitrago-Garcia D, Robles-Rodriguez W, Eslava-Schmalbach J, Salanti G, Low N
J Clin Epidemiol
. 2024 Aug;
174:111489.
PMID: 39089422
Objectives: The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, first published in 2009, has been widely endorsed and compliance is high in systematic reviews (SRs) of intervention...
12.
Siafis S, Chiocchia V, Macleod M, Austin C, Homiar A, Tinsdeall F, et al.
Wellcome Open Res
. 2024 Jul;
9:182.
PMID: 39036710
Background: Trace amine-associated receptor 1 (TAAR1) agonism shows promise for treating psychosis, prompting us to synthesise data from human and non-human studies. Methods: We co-produced a living systematic review of...
13.
Ostinelli E, Chiocchia V, Macleod M, Browning M, Harmer C, Siafis S, et al.
Wellcome Open Res
. 2024 Jul;
8:425.
PMID: 39026608
Anhedonia is a key symptom of depression, and it has been suggested as a potential target for future individualised treatments. However, much is unknown about how interventions enhancing dopaminergic pathways...
14.
Siafis S, Lorenz C, Wu H, Zhu Y, Schneider-Thoma J, Bighelli I, et al.
Syst Rev
. 2024 Jun;
13(1):165.
PMID: 38915121
Background: Non-invasive brain stimulation (NIBS) is a promising intervention for treatment-resistant schizophrenia. However, there are multiple available techniques and a comprehensive synthesis of evidence is lacking. Thus, we will conduct...
15.
Salanti G, Peter N, Tonia T, Holloway A, Darwish L, Kessler R, et al.
BMJ Ment Health
. 2024 Jun;
27(1).
PMID: 38876492
Aim: To describe the pattern of the prevalence of mental health problems during the first year of the COVID-19 pandemic and examine the impact of containment measures on these trends....
16.
Ostinelli E, Efthimiou O, Luo Y, Miguel C, Karyotaki E, Cuijpers P, et al.
Res Synth Methods
. 2024 May;
15(5):758-768.
PMID: 38724250
When studies use different scales to measure continuous outcomes, standardised mean differences (SMD) are required to meta-analyse the data. However, outcomes are often reported as endpoint or change from baseline...
17.
Tinelli M, Athanasiou A, Veroniki A, Efthimiou O, Kalliala I, Bowden S, et al.
BJOG
. 2024 Apr;
131(10):1411-1419.
PMID: 38659133
Objective: To compare the cost-effectiveness of different treatments for cervical intraepithelial neoplasia (CIN). Design: A cost-effectiveness analysis based on data available in the literature and expert opinion. Setting: England. Population:...
18.
Siafis S, McCutcheon R, Chiocchia V, Ostinelli E, Wright S, Stansfield C, et al.
Wellcome Open Res
. 2024 Apr;
8:365.
PMID: 38634067
Background: There is an urgent need to develop more effective and safer antipsychotics beyond dopamine 2 receptor antagonists. An emerging and promising approach is TAAR1 agonism. Therefore, we will conduct...
19.
Chalkou K, Hamza T, Benkert P, Kuhle J, Zecca C, Simoneau G, et al.
Res Synth Methods
. 2024 Mar;
15(4):641-656.
PMID: 38501273
Some patients benefit from a treatment while others may do so less or do not benefit at all. We have previously developed a two-stage network meta-regression prediction model that synthesized...
20.
Sahker E, Furukawa T, Luo Y, Ferreira M, Okazaki K, Chevance A, et al.
BMJ Ment Health
. 2024 Jan;
27(1).
PMID: 38191234
Background: Approximately 30% of patients experience substantial improvement in depression after 2 months without treatment, and 45% with antidepressants. The smallest worthwhile difference (SWD) refers to an intervention's smallest beneficial...